In August 2014, Translarna became the first drug to be given approval to treat the genetic cause of Duchenne muscular dystrophy, outside of a clinical trial. It has been designed to address a particular genetic mutation, called a “nonsense mutation”, causing 10-15 percent of cases of the condition.